The #1 employee-ranked health benefit* is now available from US Wellness!

US Wellness has partnered with GRAIL to offer Galleri®, the first-of-its-kind multi-cancer early-detection blood test.†

*Study demographics included 1,000 respondents, age 40+, who are employed full-time at larger organizations. GRAIL Market Research. Data of File: GA-2022-0089

Late-stage cancer costs 3X more on average to treat vs early-stage cancer.¹

The Galleri multi-cancer early detection test detects a shared cancer signal across more than 50 types of cancer, many of which are not commonly screened for today.² With a simple blood draw, the Galleri test can provide your employees early detection insights that can help them be proactive about their health.

Together with GRAIL, US Wellness is leading the fight against cancer. Employees say the Galleri test is their #1 ranked health benefit, as important as a $1,000 salary increase.*

* Study demographics included 1,000 respondents, age 40+, who are employed full-time at larger organizations.
*Data on stage-specific incidence and 5-year survival of all invasive cancers in people aged 50-79 years diagnosed between 2006-2015. Performance of MCED test in a state-trantion model (interception model) when added to usual care. Galleri does not detect all cancers.

Galleri detects a shared cancer signal across more than 50 types of cancers.²

The process is simple…


Request A Test Online

which is reviewed and approved by a provider


Blood Draw Conducted

in a partner lab, onsite event or at home


Results Returned to Provider

and shared with employee


Support Services for Positive Test Results

Treating cancer starts with knowing you have it. US Wellness is proud to bring you Galleri in the fight against cancer.

†Galleri does not detect all cancers and all cancers cannot be detected in the blood. False positive and false negative results do occur.

Important Safety Information:
The Galleri® test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / Test Information:
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

1 Reddy SR, et al. Curr Med Res Opin. 2022 Apr 20:1-10. doi: 10.1080/03007995.2022.2047536

2 Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol.

3 Hubbell E, et al. Cancer Epidemiol Biomarkers Prev. 2021;30 (3): 460-468. DOI: 10.1158/1055-9965.EPI-20-1134.. 2021;32(9):1167 – 1177. doi: 10.1016/j.annonc.2021.05.806.